Accessibility StatementSkip Navigation BOSTON and ROLLE, Switzerland, Nov. 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2025. Third Quarter  2025 Financial Results 2025 Financial Outlook Driving strong business growth in the U.S. market Revenue was $19.5 million, up 23% year-over-year Gross margin was 66.3% on a reported basis and 73.1% on an adjusted basis, compared to 67 ...